2023 World Conference on Lung Cancer (Posters)-EP14.01. Neo-Adjuvant Immunotherapy in Malignant Pleural Mesothelioma: Report on Three Cases Treated in a Single Institution

EP14.01. Neo-Adjuvant Immunotherapy in Malignant Pleural Mesothelioma: Report on Three Cases Treated in a Single Institution - PDF(Abstract)

Back to course

Pdf Summary

This presentation discusses the use of neo-adjuvant immunotherapy in the treatment of malignant pleural mesothelioma (MPM). MPM is typically treated with chemotherapy, but recent studies have shown promising results with the use of immunotherapy drugs such as Nivolumab and Ipilimumab. <br /><br />The presentation focuses on three cases of MPM patients who underwent neo-adjuvant immunotherapy at a single institution. In the first case, a 68-year-old male with left epithelioid MPM underwent standard chemotherapy followed by immunotherapy. The patient showed a metabolic response and was eligible for surgery, which resulted in a complete response with no evidence of disease relapse after one year. <br /><br />In the second case, a 55-year-old male with left epithelioid MPM received immunotherapy prior to surgery and had a partial response. However, the patient experienced a local relapse after 12 months and subsequent progression. <br /><br />The third case involved a 69-year-old male with left biphasic MPM who received immunotherapy but had disease progression that excluded him from surgery. The patient then received systemic chemotherapy. <br /><br />The results of these cases demonstrate heterogeneity in the response to immunotherapy, with a complete response observed in epithelioid MPM and progression and relapse observed in biphasic MPM. <br /><br />The presentation suggests the need for further research to identify subtypes of mesothelioma that may have a better response to immunotherapy. Additionally, transcriptomic characterization of tissue samples is underway to identify determinants for double immunotherapy in the multimodality treatment strategy. The role of surgery in an integrated treatment approach should also be investigated further. <br /><br />Overall, this study highlights the potential benefits of neo-adjuvant immunotherapy in MPM treatment, although more research is needed to optimize patient selection and treatment strategies.

Asset Subtitle

Pierluigi Novellis

Meta Tag

Speaker Pierluigi Novellis

Topic Mesothelioma, Thymoma & Other Thoracic Tumors

Keywords

neo-adjuvant immunotherapy

malignant pleural mesothelioma

chemotherapy

immunotherapy drugs

metabolic response

complete response

disease relapse

partial response

subtypes of mesothelioma

treatment strategies